BNET Industries
Market Cap:$15.4B
Last Fiscal Year Sales:$15.6B
- Public
- NL
Dow Jones Description
Akzo Nobel's paint colors turn the competition green. Founded in 1911 and headquartered in Arnhem, Netherlands, Akzo Nobel N.V. (NASDAQ: AKZOY (ADR); AMS: AKZA) is the world's largest paint maker, among other businesses. The company operates in several segments. Coatings segment produces paints, stains, chemicals, auto finishes, and synthetic resins. Pharmaceuticals segment produces prescription and over-the-counter drugs. Chemicals segment produces specialty, functional, and commodity chemicals. The company has annual revenue of about ?13 billion and employs about 61,500 people. Akzo Nobel was listed on FTSE4Good Index in 2006. In 2005 it was selected as a member of the prestigious Dow Jones Sustainability Indexes, World and Stoxx.
Chairman & CEO
G.J. WijersNumber of Employees 42,600
Peer Companies
NAICS Code Medicinal and Botanical Manufacturing: 325411
Recent Events
-
2nd UPDATE: Akzo 3Q Net Profit Up, Fiscal Year Outlook Missing
-
UPDATE: AkzoNobel 3Q Net Profit Up 30%, No Full-Year Outlook Given
-
Kemira to buy Akzo Nobel's iron coagulant business in Nordic countries
-
Akzo profit a sign chemical makers have potential to surprise
-
2nd UPDATE: AkzoNobel 2Q Net 13% Down, No Fiscal Year Outlook Given
-
Akzo Nobel reports 13% decline in 2Q net income to Euro 155 million for 2009
News & Analysis
Filter by
akzo nobel n.v. and cvc capital corp. - All News and Analysis
CVC Capital Partners
The European Commission has cleared CVC Capital Partners' purchase of Akzo Nobel's fibres unit Acordis.
CVC eyeing Acordis fiber unit.
European equity investor CVC Capital Partners is leading a consortium that is on track to acquire Akzo Nobel NV's Acordis fibers and nonwovens business by year's end. CVC funding will help Acordis grow internally and through acquisitions. Eventually, CVC foresees an initial public offering...
Acordis to be Stand-Alone Company.
Akzo Nobel nv has signed a contract to sell its Acordis fibres business to a CVC Capital Partners-led consortium CVC for EUR 825 million (about $840 million). Closing of the transaction is expected to take place around year-end. Acordis will be a Dutch company. CVC will ...
ACORDIS FIBERS SOLD TO LONDON-BASED CONSORTIUM; MOVE TAKES AKZO NOBEL OUT OF THE MAN-MADE FIBER BUSINESS.
LONDON -- Akzo Nobel NV has finally gotten out of man-made fibers. The Dutch company has signed the contract to sell its Acordis fibers division to a consortium led by CVC Capital Partners, the London-based venture capital fund. The purchase price...
Negotiations for Sale of Acordis to CVC Completed
ARNHEM, the Netherlands--BUSINESS WIRE--Nov. 18, 1999-- Akzo Nobel has signed a contract to sell its Acordis fibers business to a CVC Capital Partners led consortium CVC for EUR 825 million. The business will take along provisions of some EUR 225 million. Closing of the transaction is expected to take...
Akzo Buys Hoechst Roussel And Studies a Sale of Acordis.
The company plans to strengthen its Intervet unit. AKZO NOBEL revealed last week that it is seriously considering an [epsilon]825 million ($883 million) bid from CVC Capital Partners for its Acordis fibers business, which it has been planning to spin off. ...
AKZO RECEIVES $891M OFFER FOR ACORDIS FIBERS DIVISION.(Brief Article)
LONDON -- Akzo Nobel NV said Monday it has received an $891 million offer for its Acordis fibers division from CVC Capital Partners, Europe's largest venture capital firm. Under the terms of the bid, CVC and the management of Acordis would ...
- 1
Decision Makers
| Name (plus bio) | Position |
|---|---|
| R.J. Frohn | CFO |
| Rob Frohn | CFO |
| Keith Nichols | Senior Vice President, Finance |
| O. Werner | Senior Vice President, HR |
| Jan H. Dopper | Technology Director |
| John McLaren | Director, Corp Communications |
| M. Rooseboom | Senior Group Director, Coatings |
| Barry Oonk | Manager, Advertising |
| Bill McPherson | General Manager, Marine & Protective Coatings |
| Rob Molenaar | General Manager, Powder Coatings Business |
| A. Jan Eijsbouts | General Counsel |
| A.T.M. Wilderbeek | Member, Management Bd, Pharma |
| Han Jalink | Secretary |
| Leif Darner | Head |
| Rudy M.J. van der Meer | Member, Management Bd, Coatings |
Board of Directors
| Name (plus bio) | Position |
|---|---|
| G.J. Wijers | Chairman & CEO |
| Antony Burgmans | Supervisory Board |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | Chairman & CEO | Current |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | CFO | Current |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | CFO | Current |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | Senior Vice President, Finance | Current |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | Senior Vice President, HR | Current |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | Technology Director | Current |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | Director, Corp Communications | Current |
| Akzo Nobel N.V. | Director, Corp Communications | Former |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | Senior Group Director, Coatings | Current |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | Manager, Advertising | Current |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | General Manager, Marine & Protective Coatings | Current |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | General Manager, Powder Coatings Business | Current |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | General Counsel | Current |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | Member, Management Bd, Pharma | Current |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | Secretary | Current |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | Head | Current |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | Member, Management Bd, Coatings | Current |
| James Hardie Industries N.V. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Amoco Ultimate | Board of Directors | Current |
| Bp Alternative Energy | Board of Directors | Current |
| Air Bp Limited | Board of Directors | Current |
| Bp Refining and Petrochemical | Board of Directors | Current |
| Progas Limited | Board of Directors | Current |
| The Bp Group | Board of Directors | Current |
| Bp Solar Neighbors Program | Board of Directors | Current |
| Akzo Nobel N.V. | Supervisory Board | Current |
| Bp Solar International, Inc. | Board of Directors | Current |
| Bp Marine | Board of Directors | Current |
| AEGON N.V. | Supervisory Board | Current |
| BP plc | Board of Directors | Current |
| Wristore | Board of Directors | Current |
| Unilever N.V. | Business Group Vice President | Former |
| Unilever | Marketing Assistant | Former |
| Unilever N.V. | Chairman, Unilever Indonesia | Former |
| Unilever N.V. | Chairman | Former |
| Unilever N.V. | Vice Chairman | Former |
| Unilever Plc | Vice Chairman | Former |
| Unilever | Board of Directors | Former |
| University of Lancaster | MA | Former |
| Nijenrode University | Former | |
| University of Stockholm | Former |
| Volume | 4,400 |
| Shares Outstanding | 231.6M |
| Market Cap | 15.4B |
| Year High | 70.00 |
| Year Low | 32.15 |
| Earnings Per Share | -6.7840 |
| P/E Ratio | N/A |
| Dividend | 1.94 |
| Yield | 2.90 |
Industry Transcripts by Seeking Alpha
-
Peregrine Pharmaceuticals Inc. F2Q10 (Qtr End 31/10/09) Earnings Call Transcript
on Dec 10, 2009about PPHM
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- Why J&J's Stelara Launch Should Target Dermatologists First 3 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes
- Fired Whistleblower Reps Make Similar Claim: Pfizer Said They Lacked "Integrity" 3 votes
- More Tysabri Problems; Time for a Biogen-Idec Credibility Check 3 votes

